Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350785 | 1.00 | MMP2 (0.40) | MMP2MMP9MMP1CCR2MEN1 | |
| SCHEMBL576582 | 0.89 | ALDH1A1 (0.39) | MMP2MMP9MMP1CCR2MEN1 | |
| SCHEMBL577376 | 0.87 | AKR1C1 (0.38) | MMP2MMP9MMP1CCR2HSD11B1 | |
| SCHEMBL7034683 | 0.83 | CCR2 (0.40) | CCR2 | |
| SCHEMBL576540 | 0.80 | BRD4 (0.41) | MMP2MMP9MMP1CCR2MEN1 | |
| SCHEMBL7038682 | 0.80 | SLC6A4 (0.44) | — | |
| SCHEMBL5608693 | 0.79 | ALDH1A1 (0.35) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL7034677 | 0.78 | POLB (0.40) | HSD11B1ALDH1A1 | |
| SCHEMBL7035740 | 0.77 | HCAR2 (0.44) | KMT2AALDH1A1 | |
| SCHEMBL577105 | 0.76 | MEN1 (0.41) | MEN1CYP2C9KMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4904628-A | Components and catalysts for the polymerization of olefins | MONTEDISON S.P.A. (IT) | 1990-02-27 | — | — | US | claimed |
| JP-6192316-A | — | — | None | — | — | JP | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210194058-A1 | NONAQUEOUS ELECTROLYTE LIQUID BATTERY | MAXELL HOLDINGS, LTD. (JP) | 2021-06-24 | — | — | US | disclosed |
| CN-106848406-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-105633345-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-10468720-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190288338-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-2144321-B1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEM CORP (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-20030225282-A1 | Enantioselective process for preparing arylated lactones and derivatives | ZHANG TONY YANTAO (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1286980-A2 | ENANTIOSELECTIVE PROCESS FOR PREPARING ARYLATED LACTONES AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001072731-A2 | ENANTIOSELECTIVE PROCESS FOR PREPARING ARYLATED LACTONES AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-0756590-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | Novartis AG (CH) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995029150-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | CIBA-GEIGY AG (CH) | 1995-11-02 | — | — | WO | disclosed |
| JP-H06192316-A | CATALYST FOR ALPHA-OLEFIN POLYMERIZATION | MITSUI PETROCHEM IND LTD | 1994-07-12 | — | — | JP | disclosed |
| US-4904628-A | Components and catalysts for the polymerization of olefins | MONTEDISON S.P.A. (IT) | 1990-02-27 | — | — | US | disclosed |
| US-4585594-A | CARBONYLATION OF ALLYL ALCOHOL DERIVATIVE | BASF AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| US-4522930-A | REACTION PRODUCT OF METALOORGANIC COMPOUND OF ALUMINUM, ELECTRON-DONOR COMPOUND REACTIVE WITH MAGNESIUM CHLORIDE AND A SOLID HALOGENATED TITANIUM COMPOUND | MONTEDISON S.P.A. (IT) | 1985-06-11 | — | — | US | disclosed |
| EP-0086473-A2 | Components and catalysts for the polymerization of olefins | Montedison S.p.A. (IT) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225282-A1 | Enantioselective process for preparing arylated lactones and derivatives | CYP51A1, AHR, LSS | MMP2 4334/4885MMP9 4560/4885MMP1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.